Unlocking the Value of White Blood Cells for Heart Failure Diagnosis

Stefan Meier, Michiel Henkens, Stephane Heymans, Emma Louise Robinson*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

6 Citations (Web of Science)

Abstract

Cardiovascular disease (CVD) is the single greatest cause of mortality and morbidity worldwide. Inciting 85% of CVD fatalities is heart failure, often resulting in or from a myocardial infarction. Early detection along with pharmacological treatment and lifestyle adaptation can result in better prognosis. Biomarkers are molecular or physiological measures that indicate disease presence, status, and severity. However, not all forms of heart failure are created equal. Current mainstay biomarkers for heart failure, including NT-pro-BNP and ejection fraction, lack sensitivity for many patients. Circulating white blood cells and peripheral blood mononuclear cells (PBMCs) are emerging as surrogate biopsies, reflecting molecular changes in the heart. We discuss the advantages of PBMCs over other sources, as well as limitations and considerations. We urge medical center biobanks to collect, isolate and store circulating white blood cells as a rich source of biomarkers to catalyze the discovery of novel diagnostic tools for heart failure.

Original languageEnglish
Pages (from-to)53-62
Number of pages10
JournalJournal of Cardiovascular Translational Research
Volume14
Issue number1
Early online date4 May 2020
DOIs
Publication statusPublished - Feb 2021

Keywords

  • Heart failure
  • Biomarker
  • Diagnosis
  • Endomyocardial biopsy
  • White blood cells
  • PBMCs
  • Buffy coat
  • MONONUCLEAR-CELLS
  • DILATED CARDIOMYOPATHY
  • OXIDATIVE STRESS
  • GENE-EXPRESSION
  • IMPLEMENTATION
  • SIGNATURES
  • PROFILES
  • HEPARIN
  • RNA

Cite this